UBS Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-219
| Closed | – | – | 8668 |
|
|
2018
Q4 | $0 | Sell |
219
-2,898
| -93% | -$3.01K | ﹤0.01% | 8728 |
|
|
2018
Q3 | $4K | Buy |
3,117
+2,621
| +528% | +$4.07K | ﹤0.01% | 7633 |
|
|
2018
Q2 | $0 | Buy |
496
+322
| +185% | +$493 | ﹤0.01% | 8655 |
|
|
2018
Q1 | $0 | Sell |
174
-5,009
| -97% | -$10.5K | ﹤0.01% | 8609 |
|
|
2017
Q4 | $12K | Buy |
5,183
+3,878
| +297% | +$9.81K | ﹤0.01% | 6943 |
|
|
2017
Q3 | $4K | Sell |
1,305
-58
| -4% | -$195 | ﹤0.01% | 7369 |
|
|
2017
Q2 | $5K | Buy |
1,363
+459
| +51% | +$1.51K | ﹤0.01% | 7184 |
|
|
2017
Q1 | $3K | Sell |
904
-2,976
| -77% | -$11.6K | ﹤0.01% | 7260 |
|
|
2016
Q4 | $18K | Buy |
3,880
+3,206
| +476% | +$13.2K | ﹤0.01% | 6605 |
|
|
2016
Q3 | $3K | Sell |
674
-41
| -6% | -$133 | ﹤0.01% | 7370 |
|
|
2016
Q2 | $2K | Sell |
715
-2,091
| -75% | -$7.56K | ﹤0.01% | 7510 |
|
|
2016
Q1 | $13K | Buy |
2,806
+226
| +9% | +$875 | ﹤0.01% | 6523 |
|
|
2015
Q4 | $10K | Buy |
2,580
+2,137
| +482% | +$9.85K | ﹤0.01% | 7331 |
|
|
2015
Q3 | $2K | Sell |
443
-234
| -35% | -$1.07K | ﹤0.01% | 8172 |
|
|
2015
Q2 | $3K | Sell |
677
-4,230
| -86% | -$40.6K | ﹤0.01% | 8151 |
|
|
2015
Q1 | $33K | Buy |
4,907
+1,558
| +47% | +$7.72K | ﹤0.01% | 6475 |
|
|
2014
Q4 | $11K | Buy |
+3,349
| New | +$13.5K | ﹤0.01% | 8364 |
|
UBS Group's AST Position: Q1 2019 in Review
UBS Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 219 shares.
UBS Group first reported a position in AST in Q4 2014 and held it in 17 quarters. The position peaked at $33K in Q1 2015. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- UBS Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- UBS Group sold 219 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
- UBS Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 17 quarters.
- UBS Group's Asterias Biotherapeutics Inc. Series A position peaked at $33K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on UBS Group's 13F filing for Q1 2019, filed 14 May 2019.